Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Competing Interest Statement

L.B. participated in a Vertex Virtual Advisory Board and she is a member of the CF Annual Faculty, sponsored by Vertex Pharmaceuticals. D.M-C. received an honorarium for teaching module development for Vertex Pharmaceuticals. N. M. is doing contract research trials for Vertex Phaemaceuticals and Abbvie. A.L.S has received speaking fees for educational programs sponsored by Vertex Pharmaceuticals. B.S.Q. has received speaker fees from Vertex Pharmaceuticals and has served as site PI for several Vertex-sponsored clinical trials .W.M.L is a study investigator for Vertex Pharmaceuticals. E.T., T.G. and F.R. act as a consultant for Vertex Pharmaceuticals. M.S. participated in Vertex clinical trials and received payment for education modules. J.G., G.H., C.W., C. Bartlett, N.P., F.L., K.K., J.A., A.H., M.S., M.E., G.C.M., D.A., S.B., C.Bjornson, M.C., J.R., A.P., M.P., R.V.W., Y.B., D.H., M.J.S., J.B., P.W., L.S., E.B., T.M., J.M.R and L.J.S. have no conflicts of interest.

Funding Statement

Funding was provided by Cystic Fibrosis Foundation STRUG17PO, MORAES1610; Canadian Institutes of Health Research (FRN 167282), Cystic Fibrosis Canada (2626) and the CFIT Program funded by the SickKids Foundation and CF Canada; Natural Sciences and Engineering Research Council of Canada (RGPIN-2015- 03742, 250053-2013). This work was also funded by the Government of Canada through Genome Canada (OGI-148) and supported by a grant from the Government of Ontario. The funders of the study play no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Canadian Gene Modifier Study (CGMS) was approved by the Research Ethics Board of the Hospital for Sick Children (# 0020020214 from 2012-2019 and #1000065760 from 2019-present) and all participating sub-sites. Written informed consent was obtained from all participants or parents/guardians/substitute decision makers prior to inclusion in the study. The CGMS is approved by the Research Ethics Board of the Hospital for Sick Children for the usage of public and external data. The US PROSPECT study provides data from a clinical trial registered at clinicaltrial.gov, identifier NCT02477319, and we obtained these data through application to the US CFF at https://www.cff.org/Research/Researcher-Resources/.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes